Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06055348
Other study ID # SC0191-102
Secondary ID
Status Not yet recruiting
Phase Phase 1/Phase 2
First received
Last updated
Start date October 30, 2023
Est. completion date November 30, 2025

Study information

Verified date September 2023
Source Biocity Biopharmaceutics Co., Ltd.
Contact Xiaohua Wu
Phone 021-64175590
Email wu.xh@fudan.edu.cn
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A phase Ib/II clinical study on the safety, pharmacokinetic characteristics, and preliminary efficacy of SC0191 combination chemotherapy in patients with advanced ovarian cancer.


Description:

The phase 1b/2,multicenter, open-label study, contains 2 parts. Part 1 Dose Escalation of SC0191 combination chemotherapy: Part 1 will estimate the RP2D in dose escalation cohorts in patients withadvanced ovarian cancer. Part 2 Dose Expansion of SC0191 plus Chemotherapy.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 112
Est. completion date November 30, 2025
Est. primary completion date August 30, 2025
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Histologically or cytologically confirmed advanced ovarian cancer that has failed or intolerant or not applicable to standard treatment (applicable to the dose escalation phase of stage Ib); 2. Histologically or cytologically confirmed advanced high-grade serous ovarian cancer, platinum-resistant or platinum-refractory recurrent ovarian cancer (applicable to the dose expansion phase of stage II); 3. There is at least one measurable lesion that meets the definition of RECIST 1.1; 4. Voluntarily participate in clinical trials and sign informed consent; 5. Age =18 years; 6. ECOG score of 0 to 1; 7. Predicted life expectancy =3 months; 8. Adequate bone marrow, liver biochemistry, renal function, and coagulation status. 9. Female patients who agree to use adequate contraceptive measures. Exclusion Criteria: 1. Received chemotherapy, radiotherapy, immunotherapy or biological therapy, steroid therapy or other investigational drugs <28 days prior to the first dose of study treatment. 2. Patients who have not fully recovered from surgery according to the investigator's judgment.; 3. Patients who have previously received WEE1 inhibitor treatment; 4. Unresolved AEs or toxicities due to previous treatments; 5. Patients with contraindications or a history of severe allergies to gemcitabine or paclitaxel; 6. Known malignant CNS disease other than neurologically stable, treated brain metastases; 7. Other medical conditions or systemic diseases not suitable to participate; 8. The need for long-term therapeutic doses of anticoagulant or antiplatelet drugs; 9. Received CYP3A4 moderate or strong inhibitors or CYP3A4 moderate or strong inducers within 14 days; 10. Pregnant or lactating women.

Study Design


Intervention

Drug:
SC0191
SC0191 PO will be taken on days 1-3, 8-10, and 15-17 of each 28 day cycle.
Gemcitabine
Gemcitabine 1000 mg/m² will be administered IV on days 1, 8, and 15 of each 28 day cycle.
Paclitaxel
Paclitaxel 80 mg/m² will be administered IV on days 1, 8, and 15 of each 28 day cycle.

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Biocity Biopharmaceutics Co., Ltd.

Outcome

Type Measure Description Time frame Safety issue
Primary To investigate the safety and tolerability of SC0191 in combination with gemcitabine or paclitaxel ncidence and severity of adverse events (AEs), graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 5.0 From the first dose of study treatment until 30 days after the last dose.
Primary To identify the recommended Phase 2 dose (RP2D) of SC0191 in combination with gemcitabine or paclitaxel Incidence and severity of dose-limiting toxicities (DLTs) in DLT-evaluable subjects during Cycle 1 Through Cycle 1 (cycle is 28 days)
Secondary To investigate the plasma pharmacokinetics (PK) of SC0191 in combination with gemcitabine or paclitaxel Plasma pharmacokinetics (PK) of SC0191 in combination with chemotherapy: Single Dose SC0191 Cmax, Tmax, t1/2,AUC0-24h, AUC0-last, CL/F, Vd/F, and steady state SC0191 Ctrough, Cmax,ss, Cavg,ss, Tmax,ss, AUC0-t, Rac. Through Cycle 1 (cycle is 28 days)
Secondary To obtain estimates of clinical activity by determining the objective response rate (ORR) of SC0191 in combination with gemcitabine or paclitaxel Objective response rate (ORR) as defined by Response Evaluation Criteria in Solid Tumors RECIST version 1.1 Through completion
Secondary To obtain estimates of clinical activity by determining the time to CA125 progression of SC0191 in combination with gemcitabine or paclitaxel Time to CA125 progression according to the Gynecologic Cancer Intergroup (GCIG) criteria Through completion
Secondary To obtain estimates of clinical activity by determining the progression-free survival (PFS) of SC0191 in combination with gemcitabine or paclitaxel Progression-free survival (PFS) as defined by RECIST version 1.1 and clinical criteria Through completion
Secondary To obtain estimates of clinical activity by determining the duration of response (DOR) of SC0191 in combination with gemcitabine or paclitaxel Duration of response (DOR) as defined by Response Evaluation Criteria in Solid Tumors RECIST version 1.1 Through completion
Secondary To obtain estimates of clinical activity by determining the disease control rate (DCR) of SC0191 in combination with gemcitabine or paclitaxel Disease control rate (DCR) as defined by Response Evaluation Criteria in Solid Tumors RECIST version 1.1 Through completion
See also
  Status Clinical Trial Phase
Not yet recruiting NCT03611179 - Upfront Treatment With Chemotherapy and Bevacizumab in Advanced Ovarian Cancer Phase 2
Completed NCT04135521 - Dose-dense Chemotherapy Versus Intraperitoneal Chemotherapy as First-line Chemotherapy in Advanced Ovarian Cancer
Completed NCT01462149 - Efficacy Study of Neoadjuvant Chemotherapy to Treat Advanced Ovarian Cancer Phase 2
Terminated NCT03292172 - A Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RO6870810 and Atezolizumab (PD-L1 Antibody) in Participants With Advanced Ovarian Cancer or Triple Negative Breast Cancer Phase 1
Not yet recruiting NCT05794659 - Adjuvant Therapeutic Cancer Vaccine (AST-201, pUMVC3-hIGFBP-2) in Patients With Advanced Ovarian Cancer Phase 2
Completed NCT04360629 - Efficacy and Safety of Tranexamic Acid in Cytoreductive Surgery for Ovarian Cancer N/A
Completed NCT00516724 - Study to Assess the Safety and Tolerability of a PARP Inhibitor in Combination With Carboplatin and/or Paclitaxel Phase 1
Completed NCT03158935 - The ACTIVATE (Adoptive Cell Therapy InVigorated to Augment Tumor Eradication) Trial Phase 1
Completed NCT05775549 - A Study to Characterize the Outcomes of Olaparib Maintenance Monotherapy in Newly Diagnosed BRCAwt Ovarian Cancer
Active, not recruiting NCT03737643 - Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients Phase 3
Completed NCT01290471 - Study to Assess the Safety and Tolerability of U3-1565 in Subjects With Advanced Solid Malignant Tumors Phase 1
Recruiting NCT04862325 - SOPHIE Trial: Surgery in Ovarian Cancer With PreHabilitation In ERAS N/A
Completed NCT01989546 - Pilot Trial of BMN 673, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Deleterious BRCA Mutations Phase 1/Phase 2
Recruiting NCT04556539 - Study of SC10914 in Patients With gBRCA1/2 Mutation Advanced Ovarian Cancer Phase 2
Completed NCT03161132 - Resistant Ovarian Cancer, Olaparib and Liposomal Doxorubicin Phase 2
Active, not recruiting NCT04065009 - The IPLA-OVCA Trial, Intra-Peritoneal Local Anaesthetics in Ovarian Cancer Phase 3
Active, not recruiting NCT01844986 - Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy. Phase 3
Not yet recruiting NCT05924776 - Plasmodium Immunotherapy for Advanced Ovarian Cancer Phase 2/Phase 3
Active, not recruiting NCT03878849 - Investigation of 2X-121 in Patients With Advanced Ovarian Cancer Selected by the 2X-121 DRP® Phase 2